Revenue segments as reported by the company.

Net product sales

Alliance and other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Marketing, selling and administrative

Research and development

IPRD charge - MyoKardia acquisition

Amortization of acquired intangible assets

Other (income)/ expense, net

Acquired IPRD

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Bristol-Myers

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Bristol-Myers reports robust 2022 performance and outlines growth strategies

Bristol-Myers Squibb delivered strong financial performance in 2022, with revenue growth and key product successes driving sales to $46 billion.
The company's strategic focus on portfolio expansion, market access enhancement, and operational efficiency positions it for continued growth and value creation.
Challenges around market access, legislative impacts, and expense management require strategic attention, while opportunities in product development and market expansion offer avenues for future growth.

Bristol-Myers reports robust Q1 earnings, eyes growth amid challenges

Bristol-Myers' Q1 2023 performance reflects strong sales growth and a focus on innovation, with significant progress in pipeline development and new product launches.
While facing challenges from generic competition and operational issues, the company is well-positioned to capitalize on industry advancements and strategic opportunities for growth.
By reaffirming guidance, emphasizing strategic alignment, and pursuing new therapies, Bristol-Myers demonstrates resilience and a commitment to long-term success in the pharmaceutical market.

Bristol-Myers reports robust Q2 sales and strategic growth initiatives

Bristol-Myers' Q2 performance showcased strong sales driven by new product growth and key product successes like Opdivo and Reblozyl.
While facing challenges with certain products and revenue guidance changes, the company remains confident in its financial commitments and growth outlook.
Opportunities lie in capacity ramp-up for key products, conversion strategies for patient assistance programs, and upcoming R&D insights.
Overall, Bristol-Myers' performance, strengths, and opportunities position the company for continued growth and success in the pharmaceutical market.

Bristol-Myers reports robust Q3 performance, eyes growth opportunities

Bristol-Myers Squibb's Q3 earnings call highlighted strong performance, strategic initiatives for growth, and confidence in future prospects. Despite challenges in product performance and reimbursement, the company is optimistic about market improvements and growth opportunities. Executives are focused on driving sustainable long-term growth and expanding their product portfolio.

Bristol-Myers reports robust Q4 earnings, eyes growth through strategic initiatives

Bristol-Myers' Q4 2023 showcased strong financial performance, strategic advancements, and a focus on growth drivers like Opdivo and new launches.
Despite challenges in negotiations and market dynamics, Bristol-Myers remains poised for growth through its robust product portfolio and business development strategies.
The company's emphasis on innovation, commercial execution, and clinical progress positions Bristol-Myers for sustained growth and market leadership in the pharmaceutical industry.

Bristol-Myers meets Q1 expectations, focuses on growth opportunities

Bristol-Myers Squibb's Q1 performance met expectations with strong sales growth driven by key brands and strategic acquisitions.
Despite challenges in operating expenses and interest costs impacting income, the focus on efficiency and cost savings remains a priority.
The company's strengths lie in robust sales growth of key brands, promising pipeline advancements, and strategic capital allocation plans.
Opportunities in expanding indications, new trials, and market launches position Bristol-Myers for long-term growth and competitive advantage.

Bristol-Myers reports strong Q2 performance, bullish on pipeline growth

Bristol-Myers (BMY) showcased a robust Q2 performance, emphasizing pipeline advancements and strategic capital allocation for growth and returns.
The company is confident in navigating pricing changes and improving access dynamics for key products, while focusing on transformative medicines and operational excellence.
With a positive outlook for the year, Bristol-Myers is poised to leverage opportunities in oncology, pipeline advancements, and expanding indications for key assets.

Bristol-Myers (BMY) reports strong Q3 sales and pipeline progress

Bristol-Myers Squibb (BMY) showcased robust performance with strong sales growth and positive clinical data for pipeline programs.
The company's strategic strengths lie in operational excellence, capital allocation, and commitment to sustainable growth and innovation.
Challenges include market dynamics, competition in heart failure drugs, and translating clinical data into successful drug programs.
Opportunities abound in the growing heart failure drugs market, upcoming trial data readouts, and continued focus on portfolio growth and operational efficiency.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

Bristol Myers (BMY) announces FDA's acceptance of the sNDA seeking approval for the Krazati/Erbitux combo therapy to treat CRC patients. A final decision is expected on Jun 21, 2024.

Bristol Myers' (BMY) Krazati sNDA for CRC Gets Priority Review

Bristol Myers Squibb BMY (NYSE: BMY) reported its Q4 results earlier this month, with revenues and earnings beating the street estimates. The company reported revenue of $11.5 billion and adjusted earnings of $1.70 per share compared to the consensus estimates of $11.2 billion in sales and $1.53 profit per share.

Should You Pick Bristol Myers Squibb Stock After A 30% Fall Last Year And Q4 Beat?

JPMorgan Chase & Co

UnitedHealth Group

Picking the best stocks for beginning investors is crucial as they enter the world of long-term investing. With a myriad of options available, it's essential to focus on stocks that offer growth potential and stability.

The 3 Best Stocks Beginning Investors Can Buy: February 2024

PayPal

Tapestry

Tapestry has excellent luxury brands in its portfolio and it is coming off a record quarter. PayPal's stock has struggled, but this is still a leading company in its industry.

Got $5,000? These 3 Stocks Are Dirt Cheap Buys With Plenty of Upside

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CRC--U.S. FDA Accepts Supplemental New Drug Application for KRAZATI® (adagrasib) in Combination with Cetuximab as a Targeted Treatment Option.

U.S.

Comerica

Kinder Morgan

Philip Morris

Financial Experts Agree – The Right Credit Card Makes All The Difference (sponsored) Financial experts like Suze Orman and Dave Ramsey agree: choosing the right credit card is more important than ever.

5 Stocks That Likely Raise Their Huge Dividends in 2024

Pfizer

Pfizer and Bristol Myers Squibb have delivered poor financial results of late. Some investors might worry about the future of their dividend programs.

Is It Too Late to Buy These 2 Brilliant Passive Income Stocks?

Agree Realty

Medifast

OGE Energy

ONEOK

Vici Properties

Every month we look at companies that are delivering not only a solid dividend yield but also showing a trend of growing dividends. Companies that can consistently deliver dividend growth due to rising earnings can generate long-term wealth. February 2024's dividend screening article gives us a look at some familiar names but two new names we haven't discussed before.

February's 5 Dividend Growth Stocks With 4.75%+ Yields

Amgen

AstraZeneca

Biogen

Gilead Sciences

Novartis

Sanofi

Last October, life sciences giant Thermo Fisher Scientific (NYSE: TMO ) inadvertently laid out the case for contrarian biotech stocks. According to Reuters, the company revealed that a slump in demand from the biotech sector for its services could extend into 2024.

7 Contrarian Biotech Stocks to Consider Amid Sector Weakness

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb Prices $13 Billion of Senior Unsecured Notes.

Bristol Myers Squibb Prices $13 Billion of Senior Unsecured Notes

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb Recommends Stockholders Reject “Mini-Tender” Offer by Tutanota LLC.

Bristol Myers Squibb Recommends Stockholders Reject “Mini-Tender” Offer by Tutanota LLC

Karuna Therapeutics Inc

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Karuna Therapeutics, Inc. (NasdaqGM: KRTX) to Bristol-Myers Squibb Company (NYSE: BMY). Under the terms of the proposed transaction, shareholders of Karuna will receive $330.00 in cash for each share of Karuna that they own. KSF is seeking to determine whether this consideration and the process that led to it.

KARUNA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Karuna Therapeutics, Inc. - KRTX

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Augtyro--U.S. FDA Accepts for Priority Review Bristol Myers Squibb's Application for Augtyro™ (repotrectinib).

U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb's Application for Augtyro™ (repotrectinib) for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors

NEW YORK--(BUSINESS WIRE)-- #AI--VantAI Enters Collaboration with Bristol Myers Squibb to Accelerate Molecular Glue Drug Discovery through Artificial Intelligence.

VantAI Enters Collaboration With Bristol Myers Squibb to Accelerate Molecular Glue Drug Discovery Through Artificial Intelligence

Agilent Technologies

C.H. Robinson Worldwide

Core Laboratories Inc

Comcast

Compass Minerals

Campbell Soup

Corteva Inc

Estee Lauder

Etsy

Huntington Ingalls Industries

Hilton Worldwide Holdings

Harley-Davidson

Honeywell

International Flavors & Fragrances

InterContinental Hotels Group

Kenvue

Lockheed Martin

Marriott

McDonald's

MarketAxess Holdings

Altria

NIKE

Our 3-step process focuses on wide-moat stocks (as per Morningstar's rating).

U.S. Wide-Moat Stocks On Sale - The February 2024 Heat Map

First Trust Nasdaq Pharmaceuticals ETF 

iShares U.S. Pharmaceuticals ETF

Johnson & Johnson

Eli Lilly

Merck

Invesco Dynamic Pharmaceuticals ETF

VanEck Vectors Pharmaceutical ETF

SPDR S&P Pharmaceuticals ETF

The fourth-quarter results of the healthcare sector have been unimpressive, with earnings of companies that have reported so far down 17.7% despite 7% revenue growth. However, many industry bigwigs reported solid results, with some beating on earnings or revenues or both.

A Look at Pharma ETFs After Q4 Earnings

Axcelis Technologies

ChampionX

ACLS, BMY and CHX have been added to the Zacks Rank #5 (Strong Sell) List on February 12, 2023.

New Strong Sell Stocks for February 12th

RayzeBio Inc

PRINCETON, N.J. & SAN DIEGO--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) and RayzeBio, Inc. (Nasdaq: RYZB) today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, or HSR Act, in connection with Bristol Myers Squibb's previously announced tender offer to acquire all of the outstanding shares of RayzeBio common stock for a purchase price of $62.50 per share in cash, or approximately $4.1 billion. The expiration of the waiting peri.

Bristol Myers Squibb and RayzeBio Announce Expiration of HSR Act Waiting Period

Agios Pharmaceuticals

Alkermes

Arrowhead Pharmaceuticals

BioMarin Pharmaceutical

Unlike many other market segments, biotech stocks stand out for their direct relevance. For example, investors who typically wager on aerospace and defense plays usually aren't fighter pilots.

7 Biotech Stocks Fighting America's Deadliest Diseases

News for Bristol-Myers Stock (BMY)